APN401 cell therapy: early safety and disease-stabilization findings reported
Published in Diseases!, Drugs development & discovery, Immunology.
Published October 15, 2026.
invIOs announced on October 15 that results from two Phase 1 studies of APN401 had been published in Molecular Therapy Oncology. The experimental cell therapy uses a patient’s own peripheral blood mononuclear cells, with siRNA temporarily reducing the immune checkpoint CBL-B.
According to the company’s report, 17 patients with advanced solid tumors received treatment. No dose-limiting toxicities or grade 3 or higher treatment-related adverse events were observed. Stable disease was reported in 5 of the 10 patients evaluable under RECIST criteria.
How to interpret the findings: Stable disease is not the same as tumor shrinkage. These small, early studies do not establish that APN401 improves survival or outperforms existing care. An absence of severe treatment-related events in 17 patients also cannot exclude uncommon risks.
The announcement supports further clinical investigation, while APN401 remains an experimental approach.
Source: invIOs company announcement, October 15, 2026. This summary is based on the announcement; the complete journal article was not independently reviewed.